| Property | Value |
|---|
|
?:abstract
|
-
Objective: Ivermectin is an FDA-approved, broad-spectrum anti-parasitic agent It was originally identified as an inhibitor of interaction between the human 29 immunodeficiency virus-1 (HIV-1) integrase protein (IN) and the Importin (IMP) α/β1 30 heterodimers, which are responsible for IN nuclear import Recent studies demonstrate that ivermectin is worthy of further consideration as a possible SARS-CoV-2 antiviral Methods: We built the pathogen-host interactome and analyzed it using PHISTO We compared Ivermectin and plant molecules for their interaction with Importin α3 (IMA3) using molecular docking studies Results: A phytochemical ATRI001 with the lowest binding energy-7 290 Kcal/mol was found to be superior to Ivermectin with binding energy-4 946 Kcal/mol Conclusion: ATRI001 may be a potential anti-SARS-CoV-2 agent;however, it requires clinical evaluation
|
|
is
?:annotates
of
|
|
|
?:creator
|
|
|
?:journal
|
-
International_Journal_of_Pharmacy_and_Pharmaceutical_Sciences
|
|
?:license
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
?:source
|
|
|
?:title
|
-
Phytochemical to interact with nls binding site on ima3 to inhibit importin Α/Β1 mediated nuclear import of SARS-COV-2 cargo
|
|
?:type
|
|
|
?:who_covidence_id
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}